Office of Laboratory Animal Welfare Webinar – 21st Century Cures Act: Update on Implementation
The NIH Office of Laboratory Animal Welfare (OLAW) will be releasing their prerecorded quarterly webinar titled “21st Century Cures Act: Update on Implementation” on March 11, 2021, featuring Drs. Patricia Brown (NIH), Betty Goldentyer (USDA), and Brianna Skinner (FDA). No registration required!
In this webinar, the speakers will provide updates on the agencies’ progress in implementing the recommended measures of the 21st Century Cures Act. The 21st Century Cures Act, Section 2034(d), directed NIH, USDA, and FDA to “complete a review of applicable regulations and policies for the care and use of laborato...
Source: NIH Extramural Nexus - February 1, 2021 Category: Research Authors: NIH Staff Tags: Calendar Animal Welfare Source Type: funding
Notice to Extend the Response Date for NOT-CA-21-018 "Request for Information (RFI) Regarding Opportunities for New National Programs at the National Cancer Institutes (NCI) Frederick National Laboratory for Cancer Research"
Notice NOT-CA-21-029 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 11, 2021 Category: Research Source Type: funding
Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-109 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to provide tailored support for early stage investigators (ESIs) to initiate basic or translational research with nonhuman primates (NHPs). These awards will allow ESIs additional funds, time to generate preliminary data, and the opportunity to establish all skills needed to set up and run an NHP laboratory independently. It is expected that these awards will thereby improve an ESIs ability to secure larger research awards (e.g., R01) and will facilitate their transition to independent tenu...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 11, 2021 Category: Research Source Type: funding
Limited Competition: Revision to the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
Funding Opportunity RFA-DK-20-508 from the NIH Guide for Grants and Contracts. Type 1 diabetes (T1D) is a serious and burdensome chronic disease that usually onsets in childhood or early adulthood. Recent progress in clinical trials and understanding of T1D pathogenesis and mechanisms have created opportunities to delay the onset and progression of the disease. This supplement is intended to provide resources for the design and conduct of new intervention studies in individuals at early pre-clinical stages of T1D and in individuals with new-onset T1D through the T1D TrialNet network (TrialNet). This Funding Opportunity ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 7, 2021 Category: Research Source Type: funding
New OLAW Webinar: Developments in FOIA in the Context of Animal Research
The NIH Office of Laboratory Animal Welfare released a new 30-minute webinar discussing how Freedom of Information Act (FOIA) requests related to animal welfare compliance are handled. You can listen to an engaging discussion between OLAW Deputy Director, Dr. Axel Wolff, and NIH FOIA Program Officer, Mr. Gorka Garcia-Malene on:
Reviewing and fulfilling FOIA requests at NIH
Applying FOIA Exemptions
Recent trends in FOIA requests related to animal activities and the implications for your institution
Meeting OLAW reporting requirements without submitting additional, unnecessary information
(Source: NIH Extramural Nexus)
Source: NIH Extramural Nexus - December 14, 2020 Category: Research Authors: NIH Staff Tags: New Resources Animal Welfare FOIA OLAW webinar Source Type: funding
Dear Colleague Letter: Research Internships for Graduate Students at Air Force Research Laboratory (NSF-AFRL INTERN) Supplemental Funding Opportunity
Available Formats: HTML: https://www.nsf.gov/pubs/2021/nsf21029/nsf21029.jsp?WT.mc_id=USNSF_25&WT.mc_ev=clickPDF: https://www.nsf.gov/pubs/2021/nsf21029/nsf21029.pdf?WT.mc_id=USNSF_25&WT.mc_ev=clickDocument Number: nsf21029Public Comment: This Dear Colleague Letter (DCL) references NSF 21-013, Dear Colleague Letter: Non-Academic Research Internships for Graduate Students (INTERN) Supplemental Funding Opportunity.This is an NSF Program Announcements and Information item. (Source: NSF Program Announcements and Information)
Source: NSF Program Announcements and Information - December 11, 2020 Category: Science Source Type: funding
Aging Effects on Osteoimmunology (R01 Clinical Trials Not Allowed)
Funding Opportunity RFA-AG-22-002 from the NIH Guide for Grants and Contracts. This FOA seeks to support studies on normal and pathobiological changes in aging bone marrow that impact, or are impacted by, changes in immune function with age. Studies to be supported are in the field of osteoimmunology, which concerns the bidirectional interactions between bone and the immune system. The importance of osteoimmunology and its potential for improving the understanding of bone homeostasis is now recognized. However, most research has been conducted in young mice (3-4 months) that have not completed growth and development. Yo...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 10, 2020 Category: Research Source Type: funding
Request for Information (RFI) Regarding Opportunities for New National Programs at the National Cancer Institutes (NCI) Frederick National Laboratory for Cancer Research
Notice NOT-CA-21-018 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 23, 2020 Category: Research Source Type: funding
“All About Grants” Podcast – Alternatives to Animals
Your experimental designs are coming into focus. Sample sizes…power analyses…and treatment conditions, oh my! And, all throughout, perhaps laboratory animals are needed. But, are they? Can you actually replace them and still rigorously test the hypothesis? If not, maybe the protocol can be refined in such a way to reduce their overall numbers, while still ensuring their humane care and use?
Dr. Neera Gopee, NIH OLAW
Dr. Christine Livingston, NCATS
Considering alternatives to animals in your application is the topic of our next NIH All About Grants podcast. Drs. Neera Gopee with the NIH Office of Laboratory Animal Welfa...
Source: NIH Extramural Nexus - November 18, 2020 Category: Research Authors: NIH Staff Tags: New Resources Alternatives to Animals laboratory animal podcast Source Type: funding
NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required)
Funding Opportunity PAR-21-043 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 18, 2020 Category: Research Source Type: funding
Notice of Office of Laboratory Animal Welfare Statement on Oversight of NIH-owned Chimpanzees
Notice NOT-OD-21-022 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 5, 2020 Category: Research Source Type: funding
Developing a Culture of Safety in Biomedical Research Training
The National Institute of General Medical Sciences (NIGMS) is committed to supporting safety in the nation’s biomedical research and training environments. Last April, we shared with you resources for enhancing lab safety in biomedical research training environments. Now, in a Perspective in the current issue of Molecular Biology of the Cell (MBoC), we focus on strategies for improving laboratory safety. Some of these strategies are also applicable to other forms of safety including the prevention of harassment, intimidation, and discrimination. We frame the problem of laboratory safety using a number of recent examples ...
Source: NIH Extramural Nexus - October 15, 2020 Category: Research Authors: Michelle Bond, Alison Gammie, and Jon Lorsch Tags: blog Open Mike lab safety NIGMS Training Source Type: funding
NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-032 from the NIH Guide for Grants and Contracts. (Reissue of PAR-20-021) The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in postdoctoral position. Based on the early timeframe of eligibility, and the discouragement of inclusion of preliminary data, this NINDS F32 seeks to foster early, goal-directed planning and to encourage applicat...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 15, 2020 Category: Research Source Type: funding
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-313 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or preve...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 13, 2020 Category: Research Source Type: funding
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Funding Opportunity PAR-20-314 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated i...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 13, 2020 Category: Research Source Type: funding
